Ten Years of Vildagliptin

After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endo...

Descripción completa

Detalles Bibliográficos
Autor principal: Del Prato, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2017
Materias:
Type 2 Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813464/
https://www.ncbi.nlm.nih.gov/pubmed/29632607
http://dx.doi.org/10.17925/EE.2017.13.02.54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813464/
https://www.ncbi.nlm.nih.gov/pubmed/29632607
http://dx.doi.org/10.17925/EE.2017.13.02.54

Ejemplares similares